Aarti Drugs Limited (AARTIDRUGS) - Cash Flow Conversion Efficiency

Latest as of September 2025: 0.104x

Based on the latest financial reports, Aarti Drugs Limited (AARTIDRUGS) has a cash flow conversion efficiency ratio of 0.104x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Rs1.52 Billion ≈ $16.48 Million USD) by net assets (Rs14.69 Billion ≈ $158.82 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Aarti Drugs Limited - Cash Flow Conversion Efficiency Trend (2007–2025)

This chart illustrates how Aarti Drugs Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Aarti Drugs Limited balance sheet liabilities for a breakdown of total debt and financial obligations.

Aarti Drugs Limited Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Aarti Drugs Limited ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
DB Financial Investment Co Ltd
KO:016610
-0.116x
Bhagiradha Chemicals & Industries Limited
NSE:BHAGCHEM
0.008x
West Bancorporation
NASDAQ:WTBA
0.045x
Bohai Water Industry Co Ltd
SHE:000605
0.008x
Jiangsu Yuxing Film Tech
SHE:300305
0.058x
Chongqing Sifang New Material Co. Ltd.
SHG:605122
N/A
Shivalik Bimetal Controls Limited
NSE:SBCL
0.042x
Thessaloniki Port Authority SA
AT:OLTH
0.031x

Annual Cash Flow Conversion Efficiency for Aarti Drugs Limited (2007–2025)

The table below shows the annual cash flow conversion efficiency of Aarti Drugs Limited from 2007 to 2025. For the full company profile with market capitalisation and key ratios, see AARTIDRUGS market cap.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-03-31 Rs13.69 Billion
≈ $148.09 Million
Rs2.45 Billion
≈ $26.45 Million
0.179x -36.21%
2024-03-31 Rs12.82 Billion
≈ $138.64 Million
Rs3.59 Billion
≈ $38.82 Million
0.280x +148.83%
2023-03-31 Rs11.93 Billion
≈ $128.98 Million
Rs1.34 Billion
≈ $14.51 Million
0.113x +67.45%
2022-03-31 Rs10.36 Billion
≈ $112.07 Million
Rs696.36 Million
≈ $7.53 Million
0.067x -60.36%
2021-03-31 Rs9.13 Billion
≈ $98.78 Million
Rs1.55 Billion
≈ $16.75 Million
0.170x -55.88%
2020-03-31 Rs6.52 Billion
≈ $70.56 Million
Rs2.51 Billion
≈ $27.12 Million
0.384x +45.95%
2019-03-31 Rs5.43 Billion
≈ $58.77 Million
Rs1.43 Billion
≈ $15.47 Million
0.263x +71.88%
2018-03-31 Rs4.55 Billion
≈ $49.25 Million
Rs697.66 Million
≈ $7.54 Million
0.153x -63.96%
2017-03-31 Rs4.11 Billion
≈ $44.42 Million
Rs1.75 Billion
≈ $18.88 Million
0.425x +13.96%
2016-03-31 Rs3.57 Billion
≈ $38.65 Million
Rs1.33 Billion
≈ $14.42 Million
0.373x +9.88%
2015-03-31 Rs3.08 Billion
≈ $33.33 Million
Rs1.05 Billion
≈ $11.31 Million
0.339x -10.76%
2014-03-31 Rs2.51 Billion
≈ $27.13 Million
Rs954.26 Million
≈ $10.32 Million
0.380x +6.26%
2013-03-31 Rs2.08 Billion
≈ $22.45 Million
Rs743.10 Million
≈ $8.04 Million
0.358x +72.40%
2012-03-31 Rs1.76 Billion
≈ $19.09 Million
Rs366.41 Million
≈ $3.96 Million
0.208x +64.76%
2011-03-31 Rs1.63 Billion
≈ $17.65 Million
Rs205.60 Million
≈ $2.22 Million
0.126x -68.79%
2010-03-31 Rs1.46 Billion
≈ $15.84 Million
Rs591.20 Million
≈ $6.39 Million
0.404x -18.58%
2009-03-31 Rs1.23 Billion
≈ $13.35 Million
Rs612.10 Million
≈ $6.62 Million
0.496x +94.81%
2008-03-31 Rs1.12 Billion
≈ $12.06 Million
Rs283.87 Million
≈ $3.07 Million
0.255x -12.94%
2007-03-31 Rs1.00 Billion
≈ $10.83 Million
Rs292.69 Million
≈ $3.17 Million
0.292x --

About Aarti Drugs Limited

NSE:AARTIDRUGS India Drug Manufacturers - Specialty & Generic
Market Cap
$371.43 Million
Rs34.34 Billion INR
Market Cap Rank
#14043 Global
#669 in India
Share Price
Rs376.30
Change (1 day)
+0.79%
52-Week Range
Rs319.75 - Rs545.05
All Time High
Rs1001.57
About

Aarti Drugs Limited, through its subsidiaries, manufactures and markets active pharmaceutical ingredients (APIs), pharmaceutical intermediates, specialty chemicals, and formulations in India and internationally. The company offers aceclofenac, celecoxib, diclofenac sodium, diclodenac potassium, diclofenac diethylamine, diclofenac resinate, diclofenac epolamine, nimesulide, ciprofloxacin HCL, enro… Read more